Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 8/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.46 |
| ▸ | RELA | Q04206 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701107 | 1.00 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL12402287 | 0.84 | GAA (0.62) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL4692392 | 0.82 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL2448826 | 0.82 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL2448825 | 0.82 | ALDH1A1 (0.54) | RAB9ASMN1; SMN2NPC1NFKB1NFKB2 | |
| SCHEMBL3453341 | 0.80 | NPC1 (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL3453342 | 0.80 | NPC1 (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL13108881 | 0.80 | NPC1 (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL4702952 | 0.79 | FDPS (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MEN1 | |
| SCHEMBL7643558 | 0.79 | TRPA1 (0.42) | ALDH1A1TP53CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506195-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1506195-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-02-16 | — | — | EP | disclosed |
| US-6806265-B2 | FOR THERAPY AND PROPHYLAXIS OF HIV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-19 | — | — | US | disclosed |
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2004-01-08 | — | — | US | disclosed |
| WO-2003097644-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006071-A1 | Non-nucleoside reverse transcriptase inhibitors | CBR1, POLR2H, SUB1 | RAB9A 3942/4885SMN1; SMN2 3105/4885NPC1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.